Post-treatment symptomatic improvement of the eastern Indian ADHD probands is influenced by CYP2D6 genetic variations

Relationship between CYP2D6 genotype, activity score and phenotype in a pediatric Thai population treated with risperidone

(2021) Yaowaluck Hongkaew et al.   Scientific Reports

Effects of genetic variability of CYP2D6 on neural substrates of sustained attention during on-task activity

(2020) Roberto Viviani et al.   Translational Psychiatry

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine Therapy

(2019) Jacob T. Brown et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe

(2019) Jelena Petrović et al.   EUROPEAN JOURNAL OF HUMAN GENETICS

Attention deficit hyperactivity disorder and comorbidity: A review of literature

(2019) Sundar Gnanavel et al.   World Journal of Clinical Cases

Long-Term Tolerability and Safety of Pharmacological Treatment of Adult Attention-Deficit/Hyperactivity Disorder

(2018) Dan Edvinsson et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Genetic Polymorphisms and In Silico Mutagenesis Analyses of CYP2C9, CYP2D6, and CYPOR Genes in the Pakistani Population

(2018) Shabbir Ahmed et al.   Genes

Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison

(2017) Alain Joseph et al.   EUROPEAN CHILD & ADOLESCENT PSYCHIATRY

Differences in maintenance of response upon discontinuation across medication treatments in attention-deficit/hyperactivity disorder

(2015) Jan Buitelaar et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

ADHD pharmacogenetics across the life cycle: New findings and perspectives

(2014) Estela Maria Bruxel et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS

Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity

(2013) Danxin Wang et al.   HUMAN MOLECULAR GENETICS

Why Do Children With ADHD Discontinue Their Medication?

(2012) Sara L. Toomey et al.   CLINICAL PEDIATRICS

The Pharmacology and Clinical Outcomes of Amphetamines to Treat ADHD

(2012) Paul Hodgkins et al.   CNS DRUGS

Metabolic, toxicological, and safety considerations for drugs used to treat ADHD

(2012) Sophie Duong et al.   Expert Opinion on Drug Metabolism & Toxicology

Pharmacogenomic Diversity among Brazilians: Influence of Ancestry, Self-Reported Color, and Geographical Origin

(2012) Guilherme Suarez-Kurtz et al.   Frontiers in Pharmacology

CYP2B6SNPs are associated with methadone dose required for effective treatment of opioid addiction

(2011) Orna Levran et al.   ADDICTION BIOLOGY

Relation between therapeutic response and side effects induced by methylphenidate as observed by parents and teachers of children with ADHD

(2011) James Lee et al.   BMC Psychiatry

Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system

(2010) Magnus Ingelman-Sundberg et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Functional Characterization of 17 CYP2D6 Allelic Variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57)

(2008) K. Sakuyama et al.   DRUG METABOLISM AND DISPOSITION

Likelihood-Based Association Analysis for Nuclear Families and Unrelated Subjects with Missing Genotype Data

(2008) Frank Dudbridge   HUMAN HEREDITY

CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD

(2007) Paula T. Trzepacz et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY